Statins and myotoxicity

Current Atherosclerosis Reports

Volumn 5, Issue 2, 2003, Pages 96-100

  Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; CYTOCHROME P450; ERYTHROMYCIN; FARNESOL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPID; MEVALONIC ACID; MEVINOLIN; MUSCLE ENZYME; PRAVASTATIN; SIMVASTATIN; UBIQUINONE; PYRIDINE DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME DEFECT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LIFESTYLE; MITOCHONDRIAL ENERGY TRANSFER; MORBIDITY; MORTALITY; MUSCLE DISEASE; MYALGIA; MYOPATHY; OBESITY; PRIMARY PREVENTION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; SKELETAL MUSCLE;

CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; PYRIDINES; RHABDOMYOLYSIS;

EID: 0037645485     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0079-x     Document Type: Review

References (25)

1. Phillips PS, Haas RH, Bannykh S, et al.: Statin associated myopathy with normal creatine kinase levels. Ann intern Med 2002, 137:581-585.
2. Grundy SM: Can statins cause chronic low grade myopathy? Ann Intern Med 2002, 137:617-618.
3. Farmer JA, Torre-Antione GT: Statins and myotoxicity: potential mechanisms and clinical implications. Klin Forschung 2002, 8:87-91.
4. Hargreaves IP, Heales S: Statins and myopathy. Lancet 2002, 359:711-712.
5. Laaksonen R, Jokelainen K, Sahi T, et al.: decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995, 57:62-66.
6. Bleske BE, Willis RA, Anthony M, et al.: The effect of pravastatin and atorvastatin on coenzyme Q-10. Am Heart J 2001, 142:E2.
7. Gruer PJ, Vega JM, Mercuri MS, et al.: Concomitant use of cytochrome P450 3A inhibitors and simvastatin. Am J Cardiol 1999, 87:811-815.
8. Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG Co A reductase Inhibitor. Ann Pharmacother 2001, 35:1096-1107.
9. Davidson MH: Does differing metabolism by cytochrome P450 have clinical importance?. Curr Atheroscler Rep 2000, 2:14-19.
10. Paoletti R, Corsini A, Bellosta S: Pharmacologic interactions with statins. Atherosclerosis 2002, 3(suppl):35-40.
11. Farmer JA, Torre-Amione G: Comparative tolerability of the HMG Co A reductase inhibitors. Drug Safety 2000, 23:197-213.
12. Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998, 34:155-162.
13. Evans M, Rees A: Effects of HMG Co A reductase inhibitors on skeletal muscle: are all statins the same? Drug Safety 2002, 25:649-663.
14. Muscari A, Puddu GM, Puddu P: Lipid lowering drugs: are adverse effects predictable and reversible. Cardiology 2002, 97:115-121.
15. Holt SG, Moore KP: Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 2001, 27:803-811.
16. Holt S, Moore K: Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Exp Nephrol 2000, 8:72-76.
17. Ocose L, Luurila O, Eriksson J, et al.: Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg in patients with primary hypercholesterolemia. Curr Med Res Opin 2002, 15:228-240.
18. Evans N, Rees A: The myotoxicity of statins. Curr Opin Lipidol 2002, 13:415-420.
19. Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001, 2:205-207.
20. Isaacsohn J, Insull W, Stein E, et al.: Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol 2001, 24(9 suppl):IV1-9.
21. Pfeffer MA, Keech A, Sacks FM, et al.: Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling Project. Circulation 2002, 105:2341-2346.
22. Scandinavian Simvastatin Survival Study (4S): Randomized trial of 4,444 patients with coronary artery disease. Lancet 1994, 344:1383-1389.
23. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
24. Heart Protection Study Collaborative Group: MRC/BHS Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized, placebo-controlled trial. Lancet 2002, 360:7-22.
25. Atyros BG, Papageogriou AA, Marcouris BR, et al.: Treatment with atorvastatin to National Cholesterol Educational goal versus usual care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. Curr Med Res Opin 2002, 18:220-228.